NEW YORK (GenomeWeb) – Quidel reported after the close of the market on Tuesday that its second quarter revenues grew 11 percent year over year led by new product sales, particularly of its Sofia immunoassays.

Revenues for the three months ended June 30 increased to $34.9 million from $31.5 million in Q2 2014, above the average analysts' estimate of $34.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.